Search results
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 1 day agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 1 day agoThursday, Moderna Inc MRNA reported a first-quarter EPS loss of $(3.07), down from an income of...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 1 day agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna Shares Jump After Better-Than-Expected Sales
The Wall Street Journal· 1 day agoModerna shares shot up about 7% Thursday after reporting better-than-expected quarterly sales and signaling confidence in a sales pickup later this year....
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 2 days agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
GuruFocus.com via Yahoo Finance· 19 hours agoModerna Inc (NASDAQ:MRNA) reported a net loss of $1.2 billion for the period, compared to net income...understand, as you've communicated with large retail pharmacy, how significant ...
Moderna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline
Guru Focus· 2 days agoOn May 2, 2024, Moderna Inc (MRNA, Financial) released its 8-K filing, disclosing a challenging first quarter with total revenues of $167 million, a stark decline from $1.9 ...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 2 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 2 days agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 1 day agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter ...